Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Reference vials: BPC-157, TB-500, GHK-Cu, KPV
Combination evidence

KLOW (BPC-157 + TB-500 + GHK-Cu + KPV)

Also called KLOW blend, KLOW stack

KLOW is a marketing name for the GLOW mixture with the tripeptide KPV added. None of the four components is FDA-approved, KPV has been studied only in cells and animals, and no study of the four-component mixture was found 2. The only related experiment tested two of the components in rats and found no additive effect 1.

Not studied together in humans

Components

A pre-mixed product with these contents has its own page: KLOW Blend.

What has been studied

  • No human or animal study of the four-component mixture was found. Searched: PubMed (KPV AND (BPC OR thymosin OR GHK); GHK-Cu AND KPV) and ClinicalTrials.gov, October 2026; the hits were reviews discussing components individually.
  • The BPC-157 + TB-500 subset was compared with each peptide alone in rats, with no additional effect from the combination; GHK-Cu and KPV were not studied 1.

Why the pairing is discussed

Mechanistic reasoning drawn from studies of each component. Theoretical unless a study above tested the pair.

  • Theoretical: in human intestinal epithelial and T-cell lines, nanomolar KPV inhibited NF-kappaB and MAP kinase signalling via the PepT1 transporter, and oral KPV reduced colitis in mice 2; this anti-inflammatory profile is why KPV is added to repair-oriented mixtures.
  • Theoretical: BPC-157 (VEGFR2 signalling in embryo, cell and rat models) 3, thymosin beta-4 fragments (wound repair in mice) 4 and GHK-Cu (collagen and matrix effects in laboratory systems) 5 each have separate preclinical findings; no study shows that the four combine.

Concerns and unknowns

  • KPV in plain solution was reported to be very unstable in a rat colitis formulation study 6; how it behaves in a shared vial with three other peptides is unknown.
  • FDA states it has not identified any human exposure data for drug products containing KPV by any route, and lists it among nominated-but-withdrawn substances that may present significant safety risks; the same page lists BPC-157, TB-500 and injectable GHK-Cu, citing immunogenicity and impurity concerns 7.
  • No interaction, pharmacokinetic or safety data exist for the mixture; the only two-component animal comparison found no additive effect 1.
  • WADA's 2026 Prohibited List names BPC-157 in section S0 (non-approved substances, prohibited at all times) and 'Thymosin-beta-4 and its derivatives e.g. TB-500' in section S2.3 (growth factors and growth factor modulators). 8
  • KPV and GHK-Cu are not named on the 2026 WADA list; section S0 covers unapproved substances as a class, so their absence is not clearance 8.

Status of each component

CompoundRegulatory statusEvidenceHalf-life
BPC-157Not approved — research use onlyC—
TB-500Not approved — research use onlyC—
GHK-CuNot approved — research use onlyB—
KPVNot approved — research use onlyC—

Frequently asked questions

What does KPV add?
KPV is a three-amino-acid fragment of alpha-MSH with anti-inflammatory findings in cell lines and mouse colitis models 2. It has not been studied in humans or as part of this mixture.
Has KLOW been tested?
No study of the four-peptide mixture was found. A rat study of two components found no additive effect 1.
Is a four-peptide vial stable?
Unknown. KPV alone was reported to be very unstable in solution in a formulation study 6.
Are any KLOW components approved?
None is FDA-approved. FDA reports no human exposure data for KPV 7.
What is the athlete status?
BPC-157 and TB-500 are named on WADA's 2026 list; KPV and GHK-Cu are not named but may fall under S0 8.

References

  1. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Jt Dis Relat Surg. 2026
  2. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Gastroenterology. 2008
  3. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation J Mol Med (Berl). 2017
  4. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice Wound Repair Regen. 2003
  5. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration Biomed Res Int. 2015
  6. Self-Cross-Linked Hydrogel of Cysteamine-Grafted gamma-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats ACS Biomater Sci Eng. 2021
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA. 2026
  8. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
All combinations Compare the components side by side